Painful Diabetic Peripheral Neuropathy (PDN) Competitive Landscape –
Executive Highlights
- The tables below include an overview of the painful diabetic peripheral neuropathy (PDN) landscape, to the best of our knowledge. This condition impacts up to 50% of people with diabetes during their lifetime. In our sister organization dQ&A’s patient panel, 21% of adults with type 2 diabetes and 13% of adults with type 1 diabetes have nerve damage, which underscores the substantial need for effective neuropathy treatments.
- This list is divided into technological and pharmaceutical treatments, but we acknowledge that there are other therapies that may not encompassed in these categories.
- We will continuously update this list as needed, but it is only up to date as noted above. The included timelines are based on publicly disclosed information as indicated in the “recent coverage” column. If you see an issue, please let us know.
Table of Contents []
Therapies
| Company | Candidate | Phase | Recent Coverage |
| Applied Biologics | APPB-429 gene therapy | Preclinical |
|
| Daiichi Sankyo | Oral α2δ ligand Tarlige | Approved |
|
| Vertex | oral selective non-opioid NaV1.8 inhibitor suzetrigine (VX-548) | Phase 3 |
|
| Lexicon | AAK1 inhibitor pilavapadin (LX9211) | Ready for phase 3 |
|
| NeuroBo / MThera | NB-01 | Ready for phase 3 |
|
Technologies
| Company | Product | Recent Coverage |
| Abbott | Proclaim XR Eterna | |
| Boston Scientific | WaveWriter Alpha |
|
| DyAnys | First Relief |
|
| Medtronic | Inceptiv Intellis Vanta |
|
| Nevro | HFX-iQ HFX |
|
-- by Emily Herndon, Kat Moon, Monica Oxenreiter, Caroline Metz, and Kelly Close